1,466
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Treatment approaches for primary CNS lymphomas

, MD, , MD, , MD, , MD, , MD, , MD, , MD, , MD & , MD show all
Pages 1263-1276 | Published online: 29 Apr 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Ellen Berget, Lars Helgeland, Anne Kristine Lehmann, Alf Inge Smievoll, Olav Karsten Vintermyr & Sverre Jarl Mørk. (2013) Primary diffuse large B-cell lymphoma of the dura without systemic recurrence four years after diagnosis and successful therapy. Acta Oncologica 52:5, pages 1047-1049.
Read now
Ahmad S Halwani & Brian K Link. (2011) Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 11:3, pages 443-455.
Read now

Articles from other publishers (10)

Julia Wendler, Christopher P. Fox, Elke Valk, Cora Steinheber, Heidi Fricker, Lisa K. Isbell, Simone Neumaier, Jessica Okosun, Florian Scherer, Gabriele Ihorst, Kate Cwynarski, Elisabeth Schorb & Gerald Illerhaus. (2022) Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer 22:1.
Crossref
K. Okuyucu, E. Alagoz, S. Ince, S. Ozaydin & N. Arslan. (2018) Can metabolic tumour parameters on primary staging 18 F-FDG-PET/CT contribute to risk stratification of primary central nervous system lymphomas for patient management as a prognostic model?. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 37:1, pages 9-14.
Crossref
K. Okuyucu, E. Alagoz, S. Ince, S. Ozaydin & N. Arslan. (2018) ¿Pueden contribuir los parámetros tumorales metabólicos, establecidos mediante 18 F-FDG PET/TC para estadificación primaria, a la estratificación del riesgo de los linfomas del sistema nervioso central, para el tratamiento del paciente como modelo pronóstico?. Revista Española de Medicina Nuclear e Imagen Molecular 37:1, pages 9-14.
Crossref
B. Kasenda, A.J.M. Ferreri, E. Marturano, D. Forst, J. Bromberg, H. Ghesquieres, C. Ferlay, J.Y. Blay, K. Hoang-Xuan, E.J. Pulczynski, A. Fosså, Y. Okoshi, S. Chiba, K. Fritsch, A. Omuro, B.P. O'Neill, O. Bairey, S. Schandelmaier, V. Gloy, N. Bhatnagar, S. Haug, S. Rahner, T.T. Batchelor, G. Illerhaus & M. Briel. (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals of Oncology 26:7, pages 1305-1313.
Crossref
B. Kasenda, E. Schorb, K. Fritsch, J. Finke & G. Illerhaus. (2015) Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Annals of Oncology 26:3, pages 608-611.
Crossref
Yasuo Iwadate, Akiko Suganami, Shiro Ikegami, Natsuki Shinozaki, Tomoo Matsutani, Yutaka Tamura, Naokatsu Saeki & Ryuya Yamanaka. (2014) Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. Journal of Neuro-Oncology 117:2, pages 261-268.
Crossref
Benjamin Kasenda, Vanessa Haug, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke, Michael Mix, Claudia Hader, Wolfgang A. Weber, Gerald Illerhaus & Philipp T. Meyer. (2013) 18 F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma . Journal of Nuclear Medicine 54:2, pages 184-191.
Crossref
B. Kasenda, E. Schorb, K. Fritsch, J. Finke & G. Illerhaus. (2012) Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Annals of Oncology 23:10, pages 2670-2675.
Crossref
Avindra Nath & Joseph R. Berger. (2012) Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases. Current Treatment Options in Neurology 14:3, pages 241-255.
Crossref
Mitsuru Watanabe, Hitoshi Satoi, Yuki Takahashi, Namiko Nishida, Hiroki Toda & Sadayuki Matsumoto. (2012) Remission of lymphomatosis cerebri induced by corticosteroid and high-doses intravenous methotrexate. Rinsho Shinkeigaku 52:7, pages 486-490.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.